

## Curriculum Vitae

**Watz, Henrik** PD, Dr. med.  
d.o.b. October 07th, 1971, in Rotenburg/Fulda, Germany

### University Education

2012 Habilitation Internal Medicine, Christian-Albrechts-Universität zu Kiel (CAU)  
2001 Doctorate Medicine, Justus Liebig University Giessen (JLU)  
1991-1998 Studies of Medicine, JLU

### Scientific Career

01.09.2022 PI and Member TOLIFE, Combining Artificial Intelligence and smart sensing TOWard better management and improved quality of LIFE in chronic obstructive pulmonary disease , HORIZON-HLTH-2021-DISEASE-04-04  
Since 2021 Medical lead TELEMENTOR COPD (TELEMEdizinisches MoNiTORing) Innovationsfond G-BA/ Federal Ministry of Health  
Since 2020 Associate Editor Eur J Intern Med  
Since 2019 Founding Member and National Lead CICERO (Clinical research collaboration on COPD exacerbations) funded by the European Respiratory Society  
Since 2019 PI and Member MOBILISE-D to validate digital mobility as an outcome in clinical trials funded by the HORIZON 2020 program and EFPIA-partners  
Since 2018 Member of the COPD-Biomarker Qualification Consortium (CBQC)  
Since 2018 COPD expert for the German National Cohort (NAKO Gesundheitskohorte)  
Since 2017 Delegate of the German Society for Pneumology for the German COPD guideline  
2017–2020 Task Force Member Mobile Health, German Society for Internal Medicine  
2017-2022 Member Editorial Board Eur Respir J  
Since 2017 Member Editorial Board Am J Respir Crit Care Med  
Since 2017 Board of Chairs German Association for Outpatient Pulmonary Rehabilitation  
Since 2017 Board of Chairs German Respiratory League (Atemwegsliga)  
Since 2015 Associate Editor The Clinical Respiratory Journal  
2012-2015 Academic Editor PLOS ONE  
2012-2014 Chair, European Respiratory Society Task Force “Physical activity in COPD”  
2012 Senior Lecturer ("Privatdozent"), Venia Legendi for Internal Medicine, CAU  
Since 2011 Board of Chairs COSYCONET  
2003-2004 Internship and Residency, Internal Medicine, University Hospital Frankfurt  
2000-2002 Internship and Residency, Respiratory Medicine, Greifenstein  
1998–2000 Internship and Residency, Department of Radiology, JLU

### Awards and Honors

2018 Reviewer Award Am J Respir Crit Care Med  
2011 Award German Respiratory Society  
2005 Award Western German Respiratory Society (Curt-Dehner-Stiftung)  
2003 Award German Lung Foundation

### Citation Record

Total citations: 10,879; h-index:47; h-index since 2017: 42 (Google Scholar Aug 30<sup>th</sup>, 2022)

## Top-10 selected Publications

Andreas S, Testa M, Boyer L, Brusselle G, Janssens W, Kerwin E, Papi A, Pek B, Puente-Maestu L, Saralaya D, **Watz H**, Wilkinson TMA, Casula D, Di Maro G, Lattanzi M, Moraschini L, Schoonbroodt S, Tasciotti A, Arora AK, Maltais F; NTHi-Mcat-002 study group. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. **Lancet Respir Med**. 2022 May;10(5):435-446. doi: [10.1016/S2213-2600\(21\)00502-6](https://doi.org/10.1016/S2213-2600(21)00502-6).

Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, **Watz H**, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. **Lancet Respir Med**. 2022 Jan;10(1):11-25. doi: [10.1016/S2213-2600\(21\)00322-2](https://doi.org/10.1016/S2213-2600(21)00322-2)

Waschki B, Alter P, Zeller T, Magnussen C, Neumann JT, Twerenbold R, Sinning C, Herr C, Kahnert K, Fähndrich S, Blankenberg S, Rabe KF, Welte T, Jörres RA, Vogelmeier CF, Bals R, **Watz H**; German COSYCONET Cohort. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. **Eur Respir J**. 2020 Feb 27;55(2):1901314. doi: [10.1183/13993003.01314-2019](https://doi.org/10.1183/13993003.01314-2019).

Rabe KF, **Watz H**, Baraldo S, Pedersen F, Biondini D, Bagul N, Hanauer G, Göhring UM, Purkayastha D, Román J, Alagappan VKT, Saetta M. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. **Lancet Respir Med**. 2018 Nov;6(11):827-836. doi: [10.1016/S2213-2600\(18\)30331-X](https://doi.org/10.1016/S2213-2600(18)30331-X).

Houben-Wilke S, Jörres RA, Bals R, Franssen FM, Gläser S, Holle R, Karch A, Koch A, Magnussen H, Obst A, Schulz H, Spruit MA, Wacker ME, Welte T, Wouters EF, Vogelmeier C, **Watz H**. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. **Am J Respir Crit Care Med**. 2017 Jan 15;195(2):189-197. doi: [10.1164/rccm.201602-0354OC](https://doi.org/10.1164/rccm.201602-0354OC).

**Watz H**, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, Disse B, Finnigan H, Calverley PM. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. **Lancet Respir Med**. 2016 May;4(5):390-8. doi: [10.1016/S2213-2600\(16\)00100-4](https://doi.org/10.1016/S2213-2600(16)00100-4).

Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, **Watz H**, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. **N Engl J Med**. 2014 Oct 2;371(14):1285-94. doi: [10.1056/NEJMoa1407154](https://doi.org/10.1056/NEJMoa1407154).

**Watz H**, Pitta F, Rochester CL, Garcia-Aymerich J, ZuWallack R, Troosters T, Vaes AW, Puhan MA, Jehn M, Polkey MI, Vogiatzis I, Clini EM, Toth M, Gimeno-Santos E, Waschki B, Esteban C, Hayot M, Casaburi R, Porszasz J, McAuley E, Singh SJ, Langer D, Wouters EF, Magnussen H, Spruit MA. An official European Respiratory Society statement on physical activity in COPD. **Eur Respir J**. 2014 Dec;44(6):1521-37. doi: [10.1183/09031936.00046814](https://doi.org/10.1183/09031936.00046814).

**Watz H**, Barnacle H, Hartley BF, Chan R. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. **Lancet Respir Med**. 2014 Jan;2(1):63-72. doi: [10.1016/S2213-2600\(13\)70200-5](https://doi.org/10.1016/S2213-2600(13)70200-5).

**Watz H**, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. **Am J Respir Crit Care Med.** 2008 Apr 1;177(7):743-51. doi: [10.1164/rccm.200707-1011OC](https://doi.org/10.1164/rccm.200707-1011OC).